Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JS212 + capecitabine + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
JS212 + capecitabine + oxaliplatin is a combination therapeutic regimen being developed by Shanghai Junshi Bioscience Co., Ltd. for the treatment of metastatic colorectal cancer (mCRC). The regimen consists of JS212, a recombinant humanized bispecific antibody-drug conjugate (ADC) that targets both epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3), combined with the standard XELOX chemotherapy regimen (capecitabine and oxaliplatin). JS212 is designed to deliver a cytotoxic topoisomerase I inhibitor payload directly to tumor cells while simultaneously inhibiting EGFR and HER3 signaling pathways, which may help overcome resistance mechanisms associated with single-target therapies. This combination is currently being evaluated in Phase 2 clinical trials for patients with previously untreated microsatellite stable (MSS) or proficient mismatch repair (pMMR) metastatic colorectal cancer.
- Other names
- JS212 + XELOX
02
Targets
TS (Thymidylate synthase)ERBB3 (Erb-b2 receptor tyrosine kinase 3)DNATOP1 (DNA Topoisomerase I)EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on JS212 + capecitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JS212 + capecitabine + oxaliplatin.